NP G2 044
Alternative Names: DC-05F-01; NP-G2-044Latest Information Update: 07 Mar 2025
At a glance
- Originator Novita Pharmaceuticals; Weill Cornell Medical College
- Developer CR Double-Crane Pharmaceuticals; Novita Pharmaceuticals
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Furans; Indazoles; Small molecules
- Mechanism of Action Fascin protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Ovarian cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 25 Feb 2025 Novita Pharmaceuticals plans a phase III trial for NP G2 044 in Ovarian cancer (Combination therapy, Second-line therapy or greater) (PO) in the third quarter of 2025
- 11 Sep 2024 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06873542)
- 11 Sep 2024 Phase-I/II clinical trials in Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT06873542)